presented by

FDA approval of imported Doxil puts Endocyte’s phase 3 trial back on track

Biopharmaceutical developer Endocyte (NASDAQ:ECYT) overcame a major hurdle in its path to drug approval and can now resume enrollment in its phase 3 clinical trial of an experimental drug for ovarian cancer. The company announced Monday that U.S. regulators approved the importation of cancer drug Doxil from Europe for the study. Endocyte’s phase 3 trial […]


Cancer drug developer Endocyte files for $86M IPO

West Lafayette, Indiana, biopharmaceutical company Endocyte Inc. hopes to raise more than $86 million from an initial public offering of stock. The company that develops small-molecule drug "conjugates" to treat cancer and inflammatory diseases would use offering proceeds to pay for clinical trials, repay debt and develop its drugs.